Alks 2680

Phase 2

AAlkermes, Inc.

Alks 2680 is one of 8 therapeutic programs targeting Idiopathic Hypersomnia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Idiopathic HypersomniaRecruiting

Idiopathic HypersomniaPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Idiopathic Hypersomnia

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

—2

Romazicon

CConrado Roberto Hoffmann Filho

Approved

—3

Sunosi

AAxsome Therapeutics, Inc.

Phase 2

1 4

Low Sodium Oxybate

SStanford University

Phase 3

2 5

TAK-360

Takeda

Phase 2

2 6

FT218

AAvadel

Phase 3

1 7

ORX750

CCentessa Pharmaceuticals (UK) Limited

Phase 2

2 8

Alks 2680

AAlkermes, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Idiopathic Hypersomnia

NCT06843590

Clinical

Trials by Indication[1]

Idiopathic Hypersomnia1 trial

A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance-3)

Recruiting·AAlkermes, Inc.·Phase 2·NCT06843590·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alks 2680. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Alks 2680. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alkermes, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAlkermes, Inc.

Alks 2680

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Idiopathic Hypersomnia1 trial

References

Drug Info

Quick Facts

Related News